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In a continuing endeavor to recognize outstanding con-
tributions in the field of translational medicine, the Edi-
torial Board of the Journal of Translational Medicine
(JTM) established “T h eE x c e l l e n c ei nT r a n s l a t i o n a l
Medicine Award” in 2006 [1]. With the thought to also
recognize excellent studies, defined as those exclusively
based on the study of human subjects, the Editorial
Board has further established “The Bedside-to-Bench
Award” in 2008 [2].
The recipients of “T h eE x c e l l e n c ei nT r a n s l a t i o n a l
Medicine” and “Bedside-to-Bench” Awards will each
receive a $5,000 prize sponsored by Medistem http://
www.medisteminc.com/ and the Harry J. Lloyd Fund,
respectively. The funds received from each Award are to
be used to cover expenses for any meeting sponsored by
a non-for-profit organization that is relevant to the goal
of translational medicine and research.
Twenty-three papers nominated, including 13 highly
accessed, from investigators representative of ten coun-
tries of five continents, covering a wide range of disci-
plines published in JTM between 1 July 2008-30 June
2009 were evaluated. For this purpose, an Award Com-
mittee* comprised of eight members of the Editorial
Board selected and co-chaired by Richard J. Ablin (Uni-
versity of Arizona College of Medicine and the Arizona
Cancer Center, Tucson, AZ) and Pier Giorgio Natali
(CINBO Laboratories, “G.d’Annunzio” University, Chieti,
Italy) was formed. The initial National Institutes of
Health Scoring System of 1-5, with 1 = Outstanding and
5 = Poor, were used with the papers being evaluated
with regard to their:
￿ Scientific merit
￿ Originality
￿ Clarity
￿ Relevance to the purposes of translational medicine
and research (and in “The Bedside-to-Bench Award”
to direct study of human subjects)
￿ Research design
￿ Methodology
Excellence in Translational Medicine Award
In the paper by Hye-Won Chung [3], recipient of the
“Excellence in Translational Medicine Award for 2008-
09,” Doctor Chung and colleagueso fY o n s e iU n i v e r s i t y
College of Medicine (Seoul, Korea) and the NIH
(Bethesda, MD) have demonstrated a correlation
between the serum levels of high mobility group protein
box-1 (HMGB1) and the clinical and pathological char-
acteristics of patients with gastric cancer (GC) and its
suggested role therein as a biomarker.
Part of a group of chromosomal proteins known as
the high mobility group (HMG) encoded by the
HMBG1 gene, they are functionally involved in tran-
scription, replication, recombination and DNA repair.
HMGB1, a member of the HMG family of proteins, has
been demonstrated to serve as a cytokine mediating
lethal systemic inflammation via its extracellular release
from activated monocytes/macrophages and cells under-
going necrosis.
mRNA levels of HMGB1 are known to be overex-
pressed in tissue in the majority of patients with GC
and associated with tumour invasiveness and metastasis.
However, evaluation in tissue requires invasive techni-
ques, i.e., endoscopy and biopsy. Knowledge that
HMGB1 is released as a cytokine into the extracellular
microenvironment, suggested to Chung et al. that eva-
luation in serum might be useful.
Using an ELISA assay, Chung et al. [3] validated mea-
surement of HMGB1 as a serological biomarker for GC
and demonstrated for the first time that serum HMGB1
levels are significantly and sequentially increased in GC
in accordance with disease progression. * Correspondence: ablinrj@email.arizona.edu
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Antiretroviral therapy (ART) in HIV-infected patients,
particularly children, has resulted in increased survival.
However, as discussed in the paper by Raffaele Badolato
[4], recipient of the “Bedside-to-Bench Award 2008-09,”
and co-workers of the University of Brescia (Brescia,
Italy), poor adherence to prescriptions and the high
rates of virus replication, characteristic of perinatal HIV-
infection have been noted to contribute to higher virolo-
gical set points in children vs. adults and lower rates of
attainment of undetectable viral loads. Therefore, the
need for improved correlates of immune reconstitution
and early predictors of AR failure in HIV-infected
children.
Albeit, blood dendritic cells constitute less than 1% of
t o t a lp e r i p h e r a lb l o o dm o n o nuclear cells, they exert
relevant protection to pathogens by: i) producing IL-12
and interferon-alpha (IFN-a)a n di i )i n d u c i n gT - c e l l
immunity via presentation of pathogen-specific antigens
on their cellular surface. Additionally, IFN-a decreases
HIV replication by induction of IFN-stimulated genes,
including Myxovirus resistance 1, which encodes for the
Myxovirus resistance protein A (MxA). MxA and quan-
tification thereof as a biomarker, have been shown to
capable of inhibiting several viruses, including HIV.
With the foregoing in perspective, the study by
Badolato et al. [4] provides an exemplarly example of
translational research. Therein, they utilized real-time
PCR for measurement of MxA mRNA, a marker for the
response to IFN therapy, to monitor the presumptive
unresponsiveness of ART in perinatally HIV-infected
patients; and demonstrated that analysis of MxA may be
a valuable tool for the management of ART in perinatal
HIV-infection.
With congratulations to Hye-Won Chung [3] and to
Raffaele Badolato and their respective co-workers, the
3rd “Excellence in Translational Medicine” and 2nd
“Bedside-to-Bench” Awards are now history. We are
hopeful these Awards will serve to encourage other
investigators devoted to improving the “bench-to-
bedside” and “bedside-to-bench” concepts of transla-
tional medicine and respective initiatives.
*“Excellence in Translational Medicine and Bedside-
to-Bench Awards Committee”: Richard J. Ablin (Co-
Chairman); Howard L. Kaufman; Bruce Litman; Pier
Giorgio Natali (Co-Chairman); Hideho Okada; Michael
Perricone; Rja K. Puri; Noriyuki Sato.
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